S Gromer

Summary

Country: Germany

Publications

  1. ncbi Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium
    Stephan Gromer
    Biochemistry Center, Heidelberg University, Im Neuenheimer Feld 328, D 69120 Heidelberg, Germany
    J Biol Chem 277:9701-6. 2002
  2. ncbi Effects of antioxidants on glutathione levels and clinical recovery from the malnutrition syndrome kwashiorkor--a pilot study
    K Becker
    Department of Nutritional Biochemistry, Justus Liebig University Giessen, Giessen, Germany
    Redox Rep 10:215-26. 2005
  3. ncbi Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds
    S Gromer
    Center of Biochemistry, Heidelberg University, 69120 Heidelberg, Germany
    J Biol Chem 273:20096-101. 1998
  4. ncbi Active sites of thioredoxin reductases: why selenoproteins?
    Stephan Gromer
    Biochemie Zentrum Heidelberg, Heidelberg University, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 100:12618-23. 2003
  5. ncbi Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum
    Kathrin Buchholz
    Biochemie Zentrum der Universitat Heidelberg, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    Antimicrob Agents Chemother 52:183-91. 2008
  6. ncbi Mutational studies confirm the catalytic triad in the human selenoenzyme thioredoxin reductase predicted by molecular modeling
    Stephan Gromer
    Heidelberg University Biochemistry Center, Im Neuenheimer Feld 504, 69120 Heidelberg, Germany
    Chembiochem 7:1649-52. 2006
  7. ncbi Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors
    Régis Millet
    UMR 8525 CNRS Université Lille II Institut Pasteur de Lille, Institut de Biologie de Lille, 1 rue du Professor Calmette, BP447 59021 Lille Cedex, France
    J Med Chem 48:7024-39. 2005
  8. ncbi Human placenta thioredoxin reductase: preparation and inhibitor studies
    Stephan Gromer
    Biochemistry Center, Heidelberg University, D-69120 Heidelberg, Germany
    Methods Enzymol 347:382-94. 2002
  9. ncbi Molecular basis of glutathione reductase deficiency in human blood cells
    Nanne M Kamerbeek
    Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    Blood 109:3560-6. 2007
  10. ncbi Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum
    Kristen M Massimine
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Antimicrob Agents Chemother 50:3132-41. 2006

Collaborators

Detail Information

Publications16

  1. ncbi Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium
    Stephan Gromer
    Biochemistry Center, Heidelberg University, Im Neuenheimer Feld 328, D 69120 Heidelberg, Germany
    J Biol Chem 277:9701-6. 2002
    ..This suggests that the catalytic selenocysteine residue of mammalian thioredoxin reductase is essential for methylseleninate reduction...
  2. ncbi Effects of antioxidants on glutathione levels and clinical recovery from the malnutrition syndrome kwashiorkor--a pilot study
    K Becker
    Department of Nutritional Biochemistry, Justus Liebig University Giessen, Giessen, Germany
    Redox Rep 10:215-26. 2005
    ....
  3. ncbi Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds
    S Gromer
    Center of Biochemistry, Heidelberg University, 69120 Heidelberg, Germany
    J Biol Chem 273:20096-101. 1998
    ..At 1000-fold higher concentrations, that is at micromolar levels, the drugs also inhibited human glutathione reductase and the selenoenzyme glutathione peroxidase...
  4. ncbi Active sites of thioredoxin reductases: why selenoproteins?
    Stephan Gromer
    Biochemie Zentrum Heidelberg, Heidelberg University, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 100:12618-23. 2003
    ..Our data suggest that the selective advantage of selenoenzymes is a broader range of substrates and a broader range of microenvironmental conditions in which enzyme activity is possible...
  5. ncbi Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum
    Kathrin Buchholz
    Biochemie Zentrum der Universitat Heidelberg, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    Antimicrob Agents Chemother 52:183-91. 2008
    ..This explains the terms subversive substrate or turncoat inhibitor for MB. The results are discussed in cell-pathological and clinical contexts...
  6. ncbi Mutational studies confirm the catalytic triad in the human selenoenzyme thioredoxin reductase predicted by molecular modeling
    Stephan Gromer
    Heidelberg University Biochemistry Center, Im Neuenheimer Feld 504, 69120 Heidelberg, Germany
    Chembiochem 7:1649-52. 2006
  7. ncbi Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors
    Régis Millet
    UMR 8525 CNRS Université Lille II Institut Pasteur de Lille, Institut de Biologie de Lille, 1 rue du Professor Calmette, BP447 59021 Lille Cedex, France
    J Med Chem 48:7024-39. 2005
    ..Studies with mutant enzymes clearly demonstrate the penultimate selenocysteine residue as the prime target of the synthesized cis-diamminedichloroplatinum complexes...
  8. ncbi Human placenta thioredoxin reductase: preparation and inhibitor studies
    Stephan Gromer
    Biochemistry Center, Heidelberg University, D-69120 Heidelberg, Germany
    Methods Enzymol 347:382-94. 2002
  9. ncbi Molecular basis of glutathione reductase deficiency in human blood cells
    Nanne M Kamerbeek
    Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
    Blood 109:3560-6. 2007
    ..Studies on recombinant GR G330A revealed a drastically impaired thermostability of the protein. This is the first identification of mutations in the GR gene causing clinical GR deficiency...
  10. ncbi Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum
    Kristen M Massimine
    Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA
    Antimicrob Agents Chemother 50:3132-41. 2006
    ..In addition, preliminary studies suggest that eosin B is also acting as a redox cycling compound. Overall, our data suggest that eosin B is an effective lead compound for the development of new, more effective antimalarial drugs...
  11. ncbi Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein
    Alexey V Lobanov
    Department of Biochemistry, University of Nebraska, Lincoln, NE 68588, USA
    Nucleic Acids Res 34:4012-24. 2006
    ..Overall, these data establish that Trypanosoma, Leishmania and likely other Kinetoplastida utilize and depend on the trace element selenium, and this dependence is due to occurrence of selenium in at least three selenoproteins...
  12. ncbi The Plasmodium selenoproteome
    Alexey V Lobanov
    Department of Biochemistry, University of Nebraska, Lincoln, NE 68588, USA
    Nucleic Acids Res 34:496-505. 2006
    ..Dependence of the plasmodial parasites on selenium suggests possible strategies for antimalarial drug development...
  13. ncbi The conserved histidine 106 of large thioredoxin reductases is likely to have a structural role but not a base catalyst function
    Judit Jacob
    Biochemiezentrum der Universität Heidelberg BZH, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    FEBS Lett 579:745-8. 2005
    ..Interestingly, the phenylalanine-mutants, designed as negative controls were the most active mutants which suggests rather a structural role of His106...
  14. ncbi Thioredoxin reductase from the malaria mosquito Anopheles gambiae
    Holger Bauer
    Biochemie Zentrum, , Heidelberg, Germany
    Eur J Biochem 270:4272-81. 2003
    ..These differences offer an interesting approach to the design of species-specific inhibitors. Notably, A. gambiae thioredoxin reductase-1 is not a selenoenzyme but instead contains a highly unusual redox-active Cys-Cys sequence...
  15. ncbi The thioredoxin system--from science to clinic
    Stephan Gromer
    Biochemie Zentrum Heidelberg, Im Neuenheimer Feld 504, D 69120 Heidelberg, Germany
    Med Res Rev 24:40-89. 2004
    ..In this review we will present and evaluate the preclinical and clinical results available today. Current trends in drug development are emphasized...
  16. ncbi Cytotoxic interactions of methylene blue with trypanosomatid-specific disulfide reductases and their dithiol products
    Kathrin Buchholz
    Biochemie Zentrum der Universitat Heidelberg, INF 504, D 69120 Heidelberg, Germany
    Mol Biochem Parasitol 160:65-9. 2008
    ..Since MB is an affordable, available, and accessible drug it might be tested--alone or in drug combinations--against trypanosomatid-caused diseases of animal and man...